CDx tools provider Foundation Medicine has received FDA approval for FoundationOne CDx, a diagnostic intended for use with AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) to treat advanced breast cancer in adults.
FoundationOne CDx is a next-generation sequencing-based diagnostic device reportedly capable of analyzing over 300 cancer-related genes for genomic alterations in a patient’s tumor. The test has more than 35 companion diagnostic indications, out of which five are related to breast cancer.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.